share_log

4: Statement of changes in beneficial ownership of securities-Director Allen Charles W

4: Statement of changes in beneficial ownership of securities-Director Allen Charles W

4:持股变动声明-董事 Allen Charles W
美股sec公告 ·  05/21 20:20
Moomoo AI 已提取核心信息
On May 16, 2024, Charles W. Allen, associated with 60 Degrees Pharmaceuticals, completed a purchase of 4,000 shares of the company's common stock. The transaction was executed at a price of $0.223 per share. Following this acquisition, Allen's direct holdings in the company increased to a total of 14,000 shares. The transaction is categorized as an exercise or conversion of derivative security, and it reflects Allen's growing stake in the pharmaceutical company.
On May 16, 2024, Charles W. Allen, associated with 60 Degrees Pharmaceuticals, completed a purchase of 4,000 shares of the company's common stock. The transaction was executed at a price of $0.223 per share. Following this acquisition, Allen's direct holdings in the company increased to a total of 14,000 shares. The transaction is categorized as an exercise or conversion of derivative security, and it reflects Allen's growing stake in the pharmaceutical company.
2024年5月16日,与60度制药相关的查尔斯·艾伦完成了对该公司4,000股普通股的收购。该交易以每股0.223美元的价格执行。此次收购后,艾伦在该公司的直接持股量增加到总计14,000股。该交易被归类为衍生证券的行使或转换,它反映了艾伦在这家制药公司的股份不断增加。
2024年5月16日,与60度制药相关的查尔斯·艾伦完成了对该公司4,000股普通股的收购。该交易以每股0.223美元的价格执行。此次收购后,艾伦在该公司的直接持股量增加到总计14,000股。该交易被归类为衍生证券的行使或转换,它反映了艾伦在这家制药公司的股份不断增加。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息